aluates Reports

$ 0.0

Automative

Global Hyperimmune Globulins Market Research Report 2026

Published Date: 2026-01-16

Report Code: QYRE-Auto-13I9059

Global Hyperimmune Globulins Market Outlook 2022

BUY CHAPTERS

Global Hyperimmune Globulins Market Research Report 2026

Code: QYRE-Auto-13I9059

Report

2026-01-16

Pages:119

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

CSL Behring

Grifols S A

Biotest

Kedrion S p A

CBPO

Emergent (Cangene)

Kamada

CNBG

Hualan Bio

Shanghai Raas

Sichuan Yuanda Shuyang

ADMA Biologics

Hyperimmune Globulins Market Size

The global Hyperimmune Globulins market was valued at US$ 2058 million in 2025 and is anticipated to reach US$ 3284 million by 2032, at a CAGR of 7.0% from 2026 to 2032.

Hyperimmune Globulins Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Hyperimmune Globulins competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously. Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%. Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent. In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.

The hyperimmune globulin market is primarily driven by the increasing prevalence of infectious diseases and the rising demand for immunoglobulin therapies. These therapies are crucial in treating immunodeficiency disorders and providing passive immunity against various pathogens, which fuels market growth. Additionally, advancements in plasma-derived therapies and increasing government initiatives for immunization programs contribute to market expansion.

However, the market faces significant challenges, such as the high cost of treatment and limited availability of plasma, which is a critical raw material for hyperimmune globulin production. Moreover, stringent regulatory requirements for product approval and potential side effects associated with immunoglobulin therapies can hinder market growth.

This report delivers a comprehensive overview of the global Hyperimmune Globulins market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hyperimmune Globulins. The Hyperimmune Globulins market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Hyperimmune Globulins market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Hyperimmune Globulins manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Hyperimmune Globulins Market Report

Report Metric	Details
Report Name	Hyperimmune Globulins Market
Accounted market size in 2025	US$ 2058 million
Forecasted market size in 2032	US$ 3284 million
CAGR	7.0%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Hepatitis B Immunoglobulins Rabies Immunoglobulins Tetanus Immunoglobulins Rho(D) Immunoglobulins Herpes Zoster Immune Globulin Other
by Application	Government Institutions Private Sector Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG, Hualan Bio, Shanghai RAAS, Sichuan Yuanda Shuyang, ADMA Biologics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Hyperimmune Globulins manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Hyperimmune Globulins sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Hyperimmune Globulins Market growing?

Ans: The Hyperimmune Globulins Market witnessing a CAGR of 7.0% during the forecast period 2026-2032.

What is the Hyperimmune Globulins Market size in 2032?

Ans: The Hyperimmune Globulins Market size in 2032 will be US$ 3284 million.

What is the market share of major companies in Hyperimmune Globulins Market?

Ans: Global top two manufacturers hold a share over 50%.

Who are the main players in the Hyperimmune Globulins Market report?

Ans: The main players in the Hyperimmune Globulins Market are CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG, Hualan Bio, Shanghai RAAS, Sichuan Yuanda Shuyang, ADMA Biologics

What are the Application segmentation covered in the Hyperimmune Globulins Market report?

Ans: The Applications covered in the Hyperimmune Globulins Market report are Government Institutions, Private Sector, Other

What are the Type segmentation covered in the Hyperimmune Globulins Market report?

Ans: The Types covered in the Hyperimmune Globulins Market report are Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Tetanus Immunoglobulins, Rho(D) Immunoglobulins, Herpes Zoster Immune Globulin, Other

1 Hyperimmune Globulins Market Overview

1.1 Product Definition

1.2 Hyperimmune Globulins by Type

1.2.1 Global Hyperimmune Globulins Market Value by Type: 2025 vs 2032

1.2.2 Hepatitis B Immunoglobulins

1.2.3 Rabies Immunoglobulins

1.2.4 Tetanus Immunoglobulins

1.2.5 Rho(D) Immunoglobulins

1.2.6 Herpes Zoster Immune Globulin

1.2.7 Other

1.3 Hyperimmune Globulins by Application

1.3.1 Global Hyperimmune Globulins Market Value by Application: 2025 vs 2032

1.3.2 Government Institutions

1.3.3 Private Sector

1.3.4 Other

1.4 Global Hyperimmune Globulins Market Size Estimates and Forecasts

1.4.1 Global Hyperimmune Globulins Revenue 2021–2032

1.4.2 Global Hyperimmune Globulins Sales 2021–2032

1.4.3 Global Hyperimmune Globulins Market Average Price (2021–2032)

1.5 Assumptions and Limitations

2 Hyperimmune Globulins Market Competition by Manufacturers

2.1 Global Hyperimmune Globulins Sales Market Share by Manufacturers (2021–2026)

2.2 Global Hyperimmune Globulins Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Hyperimmune Globulins Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Hyperimmune Globulins, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Hyperimmune Globulins, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Hyperimmune Globulins, Product Types and Applications

2.7 Global Key Manufacturers of Hyperimmune Globulins, Date of Entry into the Industry

2.8 Global Hyperimmune Globulins Market Competitive Situation and Trends

2.8.1 Global Hyperimmune Globulins Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Hyperimmune Globulins Players Market Share by Revenue

2.8.3 Global Hyperimmune Globulins Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Hyperimmune Globulins Market Scenario by Region

3.1 Global Hyperimmune Globulins Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Hyperimmune Globulins Sales by Region: 2021–2032

3.2.1 Global Hyperimmune Globulins Sales by Region: 2021–2026

3.2.2 Global Hyperimmune Globulins Sales by Region: 2027–2032

3.3 Global Hyperimmune Globulins Revenue by Region: 2021–2032

3.3.1 Global Hyperimmune Globulins Revenue by Region: 2021–2026

3.3.2 Global Hyperimmune Globulins Revenue by Region: 2027–2032

3.4 North America Hyperimmune Globulins Market Facts & Figures by Country

3.4.1 North America Hyperimmune Globulins Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Hyperimmune Globulins Sales by Country (2021–2032)

3.4.3 North America Hyperimmune Globulins Revenue by Country (2021–2032)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Hyperimmune Globulins Market Facts & Figures by Country

3.5.1 Europe Hyperimmune Globulins Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Hyperimmune Globulins Sales by Country (2021–2032)

3.5.3 Europe Hyperimmune Globulins Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Hyperimmune Globulins Market Facts & Figures by Region

3.6.1 Asia Pacific Hyperimmune Globulins Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Hyperimmune Globulins Sales by Region (2021–2032)

3.6.3 Asia Pacific Hyperimmune Globulins Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Hyperimmune Globulins Market Facts & Figures by Country

3.7.1 Latin America Hyperimmune Globulins Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Hyperimmune Globulins Sales by Country (2021–2032)

3.7.3 Latin America Hyperimmune Globulins Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Hyperimmune Globulins Market Facts & Figures by Country

3.8.1 Middle East and Africa Hyperimmune Globulins Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Hyperimmune Globulins Sales by Country (2021–2032)

3.8.3 Middle East and Africa Hyperimmune Globulins Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Hyperimmune Globulins Sales by Type (2021–2032)

4.1.1 Global Hyperimmune Globulins Sales by Type (2021–2026)

4.1.2 Global Hyperimmune Globulins Sales by Type (2027–2032)

4.1.3 Global Hyperimmune Globulins Sales Market Share by Type (2021–2032)

4.2 Global Hyperimmune Globulins Revenue by Type (2021–2032)

4.2.1 Global Hyperimmune Globulins Revenue by Type (2021–2026)

4.2.2 Global Hyperimmune Globulins Revenue by Type (2027–2032)

4.2.3 Global Hyperimmune Globulins Revenue Market Share by Type (2021–2032)

4.3 Global Hyperimmune Globulins Price by Type (2021–2032)

5 Segment by Application

5.1 Global Hyperimmune Globulins Sales by Application (2021–2032)

5.1.1 Global Hyperimmune Globulins Sales by Application (2021–2026)

5.1.2 Global Hyperimmune Globulins Sales by Application (2027–2032)

5.1.3 Global Hyperimmune Globulins Sales Market Share by Application (2021–2032)

5.2 Global Hyperimmune Globulins Revenue by Application (2021–2032)

5.2.1 Global Hyperimmune Globulins Revenue by Application (2021–2026)

5.2.2 Global Hyperimmune Globulins Revenue by Application (2027–2032)

5.2.3 Global Hyperimmune Globulins Revenue Market Share by Application (2021–2032)

5.3 Global Hyperimmune Globulins Price by Application (2021–2032)

6 Key Companies Profiled

6.1 CSL Behring

6.1.1 CSL Behring Company Information

6.1.2 CSL Behring Description and Business Overview

6.1.3 CSL Behring Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 CSL Behring Hyperimmune Globulins Product Portfolio

6.1.5 CSL Behring Recent Developments/Updates

6.2 Grifols

6.2.1 Grifols Company Information

6.2.2 Grifols Description and Business Overview

6.2.3 Grifols Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Grifols Hyperimmune Globulins Product Portfolio

6.2.5 Grifols Recent Developments/Updates

6.3 Biotest

6.3.1 Biotest Company Information

6.3.2 Biotest Description and Business Overview

6.3.3 Biotest Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Biotest Hyperimmune Globulins Product Portfolio

6.3.5 Biotest Recent Developments/Updates

6.4 Kedrion

6.4.1 Kedrion Company Information

6.4.2 Kedrion Description and Business Overview

6.4.3 Kedrion Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Kedrion Hyperimmune Globulins Product Portfolio

6.4.5 Kedrion Recent Developments/Updates

6.5 CBPO

6.5.1 CBPO Company Information

6.5.2 CBPO Description and Business Overview

6.5.3 CBPO Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 CBPO Hyperimmune Globulins Product Portfolio

6.5.5 CBPO Recent Developments/Updates

6.6 Emergent (Cangene)

6.6.1 Emergent (Cangene) Company Information

6.6.2 Emergent (Cangene) Description and Business Overview

6.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Emergent (Cangene) Hyperimmune Globulins Product Portfolio

6.6.5 Emergent (Cangene) Recent Developments/Updates

6.7 Kamada

6.7.1 Kamada Company Information

6.7.2 Kamada Description and Business Overview

6.7.3 Kamada Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Kamada Hyperimmune Globulins Product Portfolio

6.7.5 Kamada Recent Developments/Updates

6.8 CNBG

6.8.1 CNBG Company Information

6.8.2 CNBG Description and Business Overview

6.8.3 CNBG Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 CNBG Hyperimmune Globulins Product Portfolio

6.8.5 CNBG Recent Developments/Updates

6.9 Hualan Bio

6.9.1 Hualan Bio Company Information

6.9.2 Hualan Bio Description and Business Overview

6.9.3 Hualan Bio Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Hualan Bio Hyperimmune Globulins Product Portfolio

6.9.5 Hualan Bio Recent Developments/Updates

6.10 Shanghai RAAS

6.10.1 Shanghai RAAS Company Information

6.10.2 Shanghai RAAS Description and Business Overview

6.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.10.4 Shanghai RAAS Hyperimmune Globulins Product Portfolio

6.10.5 Shanghai RAAS Recent Developments/Updates

6.11 Sichuan Yuanda Shuyang

6.11.1 Sichuan Yuanda Shuyang Company Information

6.11.2 Sichuan Yuanda Shuyang Description and Business Overview

6.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolio

6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates

6.12 ADMA Biologics

6.12.1 ADMA Biologics Company Information

6.12.2 ADMA Biologics Description and Business Overview

6.12.3 ADMA Biologics Hyperimmune Globulins Sales, Revenue, and Gross Margin (2021–2026)

6.12.4 ADMA Biologics Hyperimmune Globulins Product Portfolio

6.12.5 ADMA Biologics Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Hyperimmune Globulins Industry Chain Analysis

7.2 Hyperimmune Globulins Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Hyperimmune Globulins Production Mode & Process Analysis

7.4 Hyperimmune Globulins Sales and Marketing

7.4.1 Hyperimmune Globulins Sales Channels

7.4.2 Hyperimmune Globulins Distributors

7.5 Hyperimmune Globulins Customer Analysis

8 Hyperimmune Globulins Market Dynamics

8.1 Hyperimmune Globulins Industry Trends

8.2 Hyperimmune Globulins Market Drivers

8.3 Hyperimmune Globulins Market Challenges

8.4 Hyperimmune Globulins Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

CSL Behring

Grifols S A

Biotest

Kedrion S p A

CBPO

Emergent (Cangene)

Kamada

CNBG

Hualan Bio

Shanghai Raas

Sichuan Yuanda Shuyang

ADMA Biologics

List of Tables

Table 1. Global Hyperimmune Globulins Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Hyperimmune Globulins Market Value by Application (US$ Million), 2025 vs 2032

Table 3. Global Hyperimmune Globulins Market Competitive Situation by Manufacturers in 2025

Table 4. Global Hyperimmune Globulins Sales (K Units) of Key Manufacturers (2021–2026)

Table 5. Global Hyperimmune Globulins Sales Market Share by Manufacturers (2021–2026)

Table 6. Global Hyperimmune Globulins Revenue (US$ Million) by Manufacturers (2021–2026)

Table 7. Global Hyperimmune Globulins Revenue Share by Manufacturers (2021–2026)

Table 8. Global Market Hyperimmune Globulins Average Price (USD/Unit) of Key Manufacturers (2021–2026)

Table 9. Global Key Players of Hyperimmune Globulins, Industry Ranking, 2023 vs 2024 vs 2025

Table 10. Global Key Manufacturers of Hyperimmune Globulins, Manufacturing Sites and Headquarters

Table 11. Global Key Manufacturers of Hyperimmune Globulins, Product Types and Applications

Table 12. Global Key Manufacturers of Hyperimmune Globulins, Date of Entry into the Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Hyperimmune Globulins Companies by Tier (Tier 1, Tier 2, Tier 3), based on Hyperimmune Globulins Revenue, 2025

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Hyperimmune Globulins Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global Hyperimmune Globulins Sales by Region (K Units), 2021–2026

Table 18. Global Hyperimmune Globulins Sales Market Share by Region (2021–2026)

Table 19. Global Hyperimmune Globulins Sales by Region (K Units), 2027–2032

Table 20. Global Hyperimmune Globulins Sales Market Share by Region (2027–2032)

Table 21. Global Hyperimmune Globulins Revenue by Region (US$ Million), 2021–2026

Table 22. Global Hyperimmune Globulins Revenue Market Share by Region (2021–2026)

Table 23. Global Hyperimmune Globulins Revenue by Region (US$ Million), 2027–2032

Table 24. Global Hyperimmune Globulins Revenue Market Share by Region (2027–2032)

Table 25. North America Hyperimmune Globulins Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 26. North America Hyperimmune Globulins Sales by Country (K Units), 2021–2026

Table 27. North America Hyperimmune Globulins Sales by Country (K Units), 2027–2032

Table 28. North America Hyperimmune Globulins Revenue by Country (US$ Million), 2021–2026

Table 29. North America Hyperimmune Globulins Revenue by Country (US$ Million), 2027–2032

Table 30. Europe Hyperimmune Globulins Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 31. Europe Hyperimmune Globulins Sales by Country (K Units), 2021–2026

Table 32. Europe Hyperimmune Globulins Sales by Country (K Units), 2027–2032

Table 33. Europe Hyperimmune Globulins Revenue by Country (US$ Million), 2021–2026

Table 34. Europe Hyperimmune Globulins Revenue by Country (US$ Million), 2027–2032

Table 35. Asia Pacific Hyperimmune Globulins Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 36. Asia Pacific Hyperimmune Globulins Sales by Region (K Units), 2021–2026

Table 37. Asia Pacific Hyperimmune Globulins Sales by Region (K Units), 2027–2032

Table 38. Asia Pacific Hyperimmune Globulins Revenue by Region (US$ Million), 2021–2026

Table 39. Asia Pacific Hyperimmune Globulins Revenue by Region (US$ Million), 2027–2032

Table 40. Latin America Hyperimmune Globulins Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 41. Latin America Hyperimmune Globulins Sales by Country (K Units), 2021–2026

Table 42. Latin America Hyperimmune Globulins Sales by Country (K Units), 2027–2032

Table 43. Latin America Hyperimmune Globulins Revenue by Country (US$ Million), 2021–2026

Table 44. Latin America Hyperimmune Globulins Revenue by Country (US$ Million), 2027–2032

Table 45. Middle East and Africa Hyperimmune Globulins Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 46. Middle East and Africa Hyperimmune Globulins Sales by Country (K Units), 2021–2026

Table 47. Middle East and Africa Hyperimmune Globulins Sales by Country (K Units), 2027–2032

Table 48. Middle East and Africa Hyperimmune Globulins Revenue by Country (US$ Million), 2021–2026

Table 49. Middle East and Africa Hyperimmune Globulins Revenue by Country (US$ Million), 2027–2032

Table 50. Global Hyperimmune Globulins Sales (K Units) by Type (2021–2026)

Table 51. Global Hyperimmune Globulins Sales (K Units) by Type (2027–2032)

Table 52. Global Hyperimmune Globulins Sales Market Share by Type (2021–2026)

Table 53. Global Hyperimmune Globulins Sales Market Share by Type (2027–2032)

Table 54. Global Hyperimmune Globulins Revenue (US$ Million) by Type (2021–2026)

Table 55. Global Hyperimmune Globulins Revenue (US$ Million) by Type (2027–2032)

Table 56. Global Hyperimmune Globulins Revenue Market Share by Type (2021–2026)

Table 57. Global Hyperimmune Globulins Revenue Market Share by Type (2027–2032)

Table 58. Global Hyperimmune Globulins Price (USD/Unit) by Type (2021–2026)

Table 59. Global Hyperimmune Globulins Price (USD/Unit) by Type (2027–2032)

Table 60. Global Hyperimmune Globulins Sales (K Units) by Application (2021–2026)

Table 61. Global Hyperimmune Globulins Sales (K Units) by Application (2027–2032)

Table 62. Global Hyperimmune Globulins Sales Market Share by Application (2021–2026)

Table 63. Global Hyperimmune Globulins Sales Market Share by Application (2027–2032)

Table 64. Global Hyperimmune Globulins Revenue (US$ Million) by Application (2021–2026)

Table 65. Global Hyperimmune Globulins Revenue (US$ Million) by Application (2027–2032)

Table 66. Global Hyperimmune Globulins Revenue Market Share by Application (2021–2026)

Table 67. Global Hyperimmune Globulins Revenue Market Share by Application (2027–2032)

Table 68. Global Hyperimmune Globulins Price (USD/Unit) by Application (2021–2026)

Table 69. Global Hyperimmune Globulins Price (USD/Unit) by Application (2027–2032)

Table 70. CSL Behring Company Information

Table 71. CSL Behring Description and Business Overview

Table 72. CSL Behring Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 73. CSL Behring Hyperimmune Globulins Product

Table 74. CSL Behring Recent Developments/Updates

Table 75. Grifols Company Information

Table 76. Grifols Description and Business Overview

Table 77. Grifols Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 78. Grifols Hyperimmune Globulins Product

Table 79. Grifols Recent Developments/Updates

Table 80. Biotest Company Information

Table 81. Biotest Description and Business Overview

Table 82. Biotest Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 83. Biotest Hyperimmune Globulins Product

Table 84. Biotest Recent Developments/Updates

Table 85. Kedrion Company Information

Table 86. Kedrion Description and Business Overview

Table 87. Kedrion Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 88. Kedrion Hyperimmune Globulins Product

Table 89. Kedrion Recent Developments/Updates

Table 90. CBPO Company Information

Table 91. CBPO Description and Business Overview

Table 92. CBPO Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 93. CBPO Hyperimmune Globulins Product

Table 94. CBPO Recent Developments/Updates

Table 95. Emergent (Cangene) Company Information

Table 96. Emergent (Cangene) Description and Business Overview

Table 97. Emergent (Cangene) Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 98. Emergent (Cangene) Hyperimmune Globulins Product

Table 99. Emergent (Cangene) Recent Developments/Updates

Table 100. Kamada Company Information

Table 101. Kamada Description and Business Overview

Table 102. Kamada Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 103. Kamada Hyperimmune Globulins Product

Table 104. Kamada Recent Developments/Updates

Table 105. CNBG Company Information

Table 106. CNBG Description and Business Overview

Table 107. CNBG Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 108. CNBG Hyperimmune Globulins Product

Table 109. CNBG Recent Developments/Updates

Table 110. Hualan Bio Company Information

Table 111. Hualan Bio Description and Business Overview

Table 112. Hualan Bio Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 113. Hualan Bio Hyperimmune Globulins Product

Table 114. Hualan Bio Recent Developments/Updates

Table 115. Shanghai RAAS Company Information

Table 116. Shanghai RAAS Description and Business Overview

Table 117. Shanghai RAAS Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 118. Shanghai RAAS Hyperimmune Globulins Product

Table 119. Shanghai RAAS Recent Developments/Updates

Table 120. Sichuan Yuanda Shuyang Company Information

Table 121. Sichuan Yuanda Shuyang Description and Business Overview

Table 122. Sichuan Yuanda Shuyang Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 123. Sichuan Yuanda Shuyang Hyperimmune Globulins Product

Table 124. Sichuan Yuanda Shuyang Recent Developments/Updates

Table 125. ADMA Biologics Company Information

Table 126. ADMA Biologics Description and Business Overview

Table 127. ADMA Biologics Hyperimmune Globulins Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)

Table 128. ADMA Biologics Hyperimmune Globulins Product

Table 129. ADMA Biologics Recent Developments/Updates

Table 130. Key Raw Materials Lists

Table 131. Raw Materials Key Suppliers Lists

Table 132. Hyperimmune Globulins Distributors List

Table 133. Hyperimmune Globulins Customers List

Table 134. Hyperimmune Globulins Market Trends

Table 135. Hyperimmune Globulins Market Drivers

Table 136. Hyperimmune Globulins Market Challenges

Table 137. Hyperimmune Globulins Market Restraints

Table 138. Research Programs/Design for This Report

Table 139. Key Data Information from Secondary Sources

Table 140. Key Data Information from Primary Sources

Table 141. Authors List of This Report

List of Figures

Figure 1. Product Picture of Hyperimmune Globulins

Figure 2. Global Hyperimmune Globulins Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Hyperimmune Globulins Market Share by Type: 2025 & 2032

Figure 4. Hepatitis B Immunoglobulins Product Picture

Figure 5. Rabies Immunoglobulins Product Picture

Figure 6. Tetanus Immunoglobulins Product Picture

Figure 7. Rho(D) Immunoglobulins Product Picture

Figure 8. Herpes Zoster Immune Globulin Product Picture

Figure 9. Other Product Picture

Figure 10. Global Hyperimmune Globulins Market Value by Application (US$ Million), 2021–2032

Figure 11. Global Hyperimmune Globulins Market Share by Application: 2025 & 2032

Figure 12. Government Institutions

Figure 13. Private Sector

Figure 14. Other

Figure 15. Global Hyperimmune Globulins Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 16. Global Hyperimmune Globulins Market Size (US$ Million), 2021–2032

Figure 17. Global Hyperimmune Globulins Sales (K Units), 2021–2032

Figure 18. Global Hyperimmune Globulins Average Price (USD/Unit), 2021–2032

Figure 19. Hyperimmune Globulins Report Years Considered

Figure 20. Hyperimmune Globulins Sales Share by Manufacturers in 2025

Figure 21. Global Hyperimmune Globulins Revenue Share by Manufacturers in 2025

Figure 22. Top 5 and Top 10 Global Hyperimmune Globulins Players: Market Share by Revenue in Hyperimmune Globulins in 2025

Figure 23. Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 24. Global Hyperimmune Globulins Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 25. North America Hyperimmune Globulins Sales Market Share by Country (2021–2032)

Figure 26. North America Hyperimmune Globulins Revenue Market Share by Country (2021–2032)

Figure 27. U.S. Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 28. Canada Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 29. Europe Hyperimmune Globulins Sales Market Share by Country (2021–2032)

Figure 30. Europe Hyperimmune Globulins Revenue Market Share by Country (2021–2032)

Figure 31. Germany Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 32. France Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 33. U.K. Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 34. Italy Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 35. Russia Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 36. Asia Pacific Hyperimmune Globulins Sales Market Share by Region (2021–2032)

Figure 37. Asia Pacific Hyperimmune Globulins Revenue Market Share by Region (2021–2032)

Figure 38. China Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. Japan Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. South Korea Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. India Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Australia Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. China Taiwan Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 44. Indonesia Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 45. Thailand Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Malaysia Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. Philippines Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Latin America Hyperimmune Globulins Sales Market Share by Country (2021–2032)

Figure 49. Latin America Hyperimmune Globulins Revenue Market Share by Country (2021–2032)

Figure 50. Mexico Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. Brazil Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 52. Argentina Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 53. Middle East and Africa Hyperimmune Globulins Sales Market Share by Country (2021–2032)

Figure 54. Middle East and Africa Hyperimmune Globulins Revenue Market Share by Country (2021–2032)

Figure 55. Turkey Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 56. Saudi Arabia Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 57. U.A.E Hyperimmune Globulins Revenue Growth Rate (US$ Million), 2021–2032

Figure 58. Global Sales Market Share of Hyperimmune Globulins by Type (2021–2032)

Figure 59. Global Revenue Market Share of Hyperimmune Globulins by Type (2021–2032)

Figure 60. Global Hyperimmune Globulins Price (USD/Unit) by Type (2021–2032)

Figure 61. Global Sales Market Share of Hyperimmune Globulins by Application (2021–2032)

Figure 62. Global Revenue Market Share of Hyperimmune Globulins by Application (2021–2032)

Figure 63. Global Hyperimmune Globulins Price (USD/Unit) by Application (2021–2032)

Figure 64. Hyperimmune Globulins Value Chain

Figure 65. Channels of Distribution (Direct Vs Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Human Hyperimmune Globulins Market Research Report 2024

Global Hyperimmune Globulin Product Market Research Report 2024

Global Hyperimmune Globulin Injection Market Research Report 2024

Human Plasma derived Hyperimmune Product Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Human Plasma based Hyperimmune Preparation Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Intravenous Immunoglobulin IVIg Market Research Report 2025

Global Intravenous Immune Globulin Therapies Market Research Report 2024

IVIg Liquid Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Human Rabies Immune Globulin HRIG Market Research Report 2024

IVIg Powder Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Intravenous Antibodies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lyophilized IVIG Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Human Immune Globulin Intravenous Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Immune Globulin Intravenous Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Prophylactic Gamma Globulin Market Research Report 2024

Human Varicella Zoster Immunoglobulin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Human Normal Immunoglobulin Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Human Immumoglobulin PH4 for Intravenous Injection Market Insights Forecast to 2030

Animal derived Immune Globulin Products Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions